BOCA RATON, Fla., Aug. 23, 2017 — Sensus Healthcare, Inc. (Nasdaq:SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), has been invited to present at the 2017 Gateway Conference, which is being held on September 6-7, 2017 at the Four Seasons Hotel San Francisco.
Joseph Sardano, President and CEO of Sensus Healthcare, is scheduled to present on Wednesday, September 6 at 11:30 a.m. Pacific time, with one-on-one meetings held throughout the conference.
The presentation will be webcast live and available for replay in the Investor Relations section of the Company’s website at sensushealthcare.com or on the Gateway Conference website at www.gateway-conference.com/presenters.
To receive additional information, request an invitation or to schedule a one-on-one meeting, please email [email protected].
About the Gateway Conference
The 6th Annual Gateway Conference is an invite-only conference presented by Liolios, which brings together the most compelling companies with the nation’s top institutional investors and analysts. This year’s event features more than 100 companies from a number of growth industries, including technology, business and financial services, consumer, digital media, clean technology and life sciences. The format has been designed to give attendees direct access to senior management via company presentations, Q&A sessions and one-on-one meetings. For more information, visit www.gateway-conference.com or www.liolios.com.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit http://17s.9e1.myftpupload.com.
Contact: LHA Investor Relations Kim Sutton Golodetz (212) 838-3777 [email protected]